Overall survival was significantly worse for men with breast cancer than for their women counterparts.
Clinicians have been taught, with some caveats, that treatments and outcomes are very similar between men and women with breast cancer. However, recent studies have called this assumption into question.
Now, investigators have conducted a large cohort study using National Cancer Database (NCDB) data to compare mortality and methodologies between 16,000 men and 1.8 million women with breast cancer during a 10-year period. Men were older than women counterparts (63.3 vs. 59.9 years) and more likely to have ductal histology, higher-stage disease at diagnosis (stage III, 14.0% vs. 8.9%; stage IV, 5.8% vs. 3.8%), ER-positive disease, and higher recurrence score.
At a median follow-up of 54 months for men and 60 months for women, overall survival (…
Reviewing Author
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)